Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

N Lizak; A Lugaresi; R Alroughani; J Lechner-Scott; M Slee; E Havrdova; D Horakova; M Trojano; G Izquierdo; P Duquette; M Girard; A Prat; P Grammond; R Hupperts; F Grand'Maison; P Sola; E Pucci; R Bergamaschi; C Oreja-Guevara; V Van Pesch; C Ramo; D Spitaleri; G Iuliano; C Boz; F Granella; J Olascoaga; F Verheul; C Rozsa; E Cristiano; S Flechter; S Hodgkinson; MP Amato; N Deri; V Jokubaitis; T Spelman; H Butzkueven; T Kalincik

Journal article

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

N Lizak, A Lugaresi, R Alroughani, J Lechner-Scott, M Slee, E Havrdova, D Horakova, M Trojano, G Izquierdo, P Duquette, M Girard, A Prat, P Grammond, R Hupperts, F Grand'Maison, P Sola, E Pucci, R Bergamaschi, C Oreja-Guevara, V Van Pesch Show all

Journal of Neurology Neurosurgery and Psychiatry | BMJ PUBLISHING GROUP | Published : 2017

DOI: 10.1136/jnnp-2016-313976

Download PDF

Abstract

Objective: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. Methods The epochs between Expanded Disability Status Scale (EDSS) steps 3.6, 4.6 and 6.6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/6) were identified in MSBase, a global observational MS cohort study. We used multivariable survival models to examine the impact of disease-modifying therapy, clinical and demographic factors on progression to the outcome EDSS step (6/6.5). Sensitivity analyses with varying outcome definitions and incl..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Tomas Kalincik Author

Related Projects (2)

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

Grants

Awarded by Merck

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council (practitioner fellowship 1080518, project grants 1083539 and 1032484 and centre for research excellence 1001216), and University of Melbourne Research Fellowship. The MSBase Foundation is a not-for-profit organisation that receives support from Merck, Biogen, Novartis, Bayer-Schering and Sanofi. The study was conducted separately and apart from the guidance of the sponsors.